You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameAmineptine
Accession NumberDB04836
TypeSmall Molecule
GroupsIllicit, Withdrawn
DescriptionThe Food and Drug Administration suspended the marketing authorisation for Survector in 1999 and France withdrew it from the market, however several developing countries continued to produce it up until 2005.
Structure
Thumb
SynonymsNot Available
External Identifiers Not Available
Approved Prescription ProductsNot Available
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
DirectimNot Available
ManeonNot Available
NeoliorNot Available
ProvectorNot Available
SurvectorServier
ViasperaNot Available
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Amineptine hydrochloride
Thumb
  • InChI Key: VDPUXONTAVMIKZ-UHFFFAOYSA-N
  • Monoisotopic Mass: 373.180856852
  • Average Mass: 373.916
DBSALT000803
Categories
UNII27T1I13L6G
CAS number57574-09-1
WeightAverage: 373.916
Monoisotopic: 373.180856852
Chemical FormulaC22H28ClNO2
InChI KeyVDPUXONTAVMIKZ-UHFFFAOYSA-N
InChI
InChI=1S/C22H27NO2.ClH/c24-21(25)13-3-1-2-8-16-23-22-19-11-6-4-9-17(19)14-15-18-10-5-7-12-20(18)22;/h4-7,9-12,22-23H,1-3,8,13-16H2,(H,24,25);1H
IUPAC Name
N-(6-carboxyhexyl)tricyclo[9.4.0.0³,⁸]pentadeca-1(15),3,5,7,11,13-hexaen-2-aminium chloride
SMILES
[Cl-].OC(=O)CCCCCC[NH2+]C1C2=CC=CC=C2CCC2=CC=CC=C12
Pharmacology
IndicationFor the treatment of depression.
Structured Indications Not Available
PharmacodynamicsAmineptine is an atypical tricyclic antidepressant.
Mechanism of actionAmineptine selectively inhibits the reuptake of dopamine and to a lesser extent norepinephrine, thus exerting a powerful and fast-acting antidepressant effect.
TargetKindPharmacological actionActionsOrganismUniProt ID
Sodium-dependent noradrenaline transporterProteinunknownNot AvailableHumanP23975 details
Sodium-dependent serotonin transporterProteinunknownNot AvailableHumanP31645 details
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein bindingNot Available
Metabolism

Hepatic.

Route of eliminationNot Available
Half life48 minutes for the parent drug and 2.5 hours for the metabolites.
ClearanceNot Available
ToxicityNot Available
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
1,10-PhenanthrolineThe serum concentration of Amineptine can be increased when it is combined with 1,10-Phenanthroline.Experimental
2,5-Dimethoxy-4-ethylamphetamineAmineptine may increase the stimulatory activities of 2,5-Dimethoxy-4-ethylamphetamine.Experimental, Illicit
3,4-DichloroisocoumarinThe serum concentration of Amineptine can be increased when it is combined with 3,4-Dichloroisocoumarin.Experimental
3,4-MethylenedioxyamphetamineAmineptine may increase the stimulatory activities of 3,4-Methylenedioxyamphetamine.Experimental, Illicit
3,4-MethylenedioxymethamphetamineAmineptine may increase the stimulatory activities of 3,4-Methylenedioxymethamphetamine.Experimental, Illicit
4-(2-AMINOETHYL)BENZENESULFONYL FLUORIDEThe serum concentration of Amineptine can be increased when it is combined with 4-(2-AMINOETHYL)BENZENESULFONYL FLUORIDE.Experimental
4-Bromo-2,5-dimethoxyamphetamineAmineptine may increase the stimulatory activities of 4-Bromo-2,5-dimethoxyamphetamine.Experimental, Illicit
4-MethoxyamphetamineAmineptine may decrease the antihypertensive activities of 4-Methoxyamphetamine.Experimental, Illicit
7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE may increase the serotonergic activities of Amineptine.Experimental
AcenocoumarolAmineptine may increase the anticoagulant activities of Acenocoumarol.Approved
AgmatineAmineptine may decrease the antihypertensive activities of Agmatine.Experimental, Investigational
AlogliptinThe serum concentration of Amineptine can be increased when it is combined with Alogliptin.Approved
Alpha-1-proteinase inhibitorThe serum concentration of Amineptine can be increased when it is combined with Alpha-1-proteinase inhibitor.Approved
AltretamineAltretamine may increase the orthostatic hypotensive activities of Amineptine.Approved
AmobarbitalThe metabolism of Amineptine can be increased when combined with Amobarbital.Approved, Illicit
AmphetamineAmineptine may increase the stimulatory activities of Amphetamine.Approved, Illicit
AmprenavirThe serum concentration of Amineptine can be increased when it is combined with Amprenavir.Approved
Antithrombin III humanThe serum concentration of Amineptine can be increased when it is combined with Antithrombin III human.Approved
ApixabanThe serum concentration of Amineptine can be increased when it is combined with Apixaban.Approved
ApomorphineAmineptine may decrease the antihypertensive activities of Apomorphine.Approved, Investigational
ApraclonidineAmineptine may decrease the antihypertensive activities of Apraclonidine.Approved
AprotininThe serum concentration of Amineptine can be increased when it is combined with Aprotinin.Approved, Withdrawn
ArbutamineThe risk or severity of adverse effects can be increased when Amineptine is combined with Arbutamine.Approved
ArformoterolThe risk or severity of adverse effects can be increased when Amineptine is combined with Arformoterol.Approved, Investigational
ArgatrobanThe serum concentration of Amineptine can be increased when it is combined with Argatroban.Approved, Investigational
AsunaprevirThe serum concentration of Amineptine can be increased when it is combined with Asunaprevir.Approved, Investigational
AtazanavirThe serum concentration of Amineptine can be increased when it is combined with Atazanavir.Approved, Investigational
BambuterolThe risk or severity of adverse effects can be increased when Amineptine is combined with Bambuterol.Approved
BarbexacloneThe metabolism of Amineptine can be increased when combined with Barbexaclone.Experimental
BarbitalThe metabolism of Amineptine can be increased when combined with Barbital.Illicit
BatimastatThe serum concentration of Amineptine can be increased when it is combined with Batimastat.Experimental
BenazeprilThe serum concentration of Amineptine can be increased when it is combined with Benazepril.Approved, Investigational
BenmoxinBenmoxin may increase the serotonergic activities of Amineptine.Withdrawn
BenzamidineThe serum concentration of Amineptine can be increased when it is combined with Benzamidine.Experimental
BenzphetamineAmineptine may decrease the antihypertensive activities of Benzphetamine.Approved, Illicit
BethanidineAmineptine may decrease the antihypertensive activities of Bethanidine.Approved
Bi201335The serum concentration of Amineptine can be increased when it is combined with Bi201335.Investigational
BivalirudinThe serum concentration of Amineptine can be increased when it is combined with Bivalirudin.Approved, Investigational
BoceprevirThe serum concentration of Amineptine can be increased when it is combined with Boceprevir.Approved
BrimonidineAmineptine may decrease the antihypertensive activities of Brimonidine.Approved
BrimonidineThe therapeutic efficacy of Brimonidine can be decreased when used in combination with Amineptine.Approved
BromocriptineAmineptine may decrease the antihypertensive activities of Bromocriptine.Approved, Investigational
BupropionThe metabolism of Amineptine can be decreased when combined with Bupropion.Approved
CandoxatrilThe serum concentration of Amineptine can be increased when it is combined with Candoxatril.Experimental
CandoxatrilatThe serum concentration of Amineptine can be increased when it is combined with Candoxatrilat.Experimental
CaptoprilThe serum concentration of Amineptine can be increased when it is combined with Captopril.Approved
CarbamazepineThe metabolism of Amineptine can be increased when combined with Carbamazepine.Approved, Investigational
CaroxazoneCaroxazone may increase the serotonergic activities of Amineptine.Withdrawn
CeliprololThe risk or severity of adverse effects can be increased when Amineptine is combined with Celiprolol.Approved, Investigational
ChlorphentermineAmineptine may increase the stimulatory activities of Chlorphentermine.Illicit, Withdrawn
ChymostatinThe serum concentration of Amineptine can be increased when it is combined with Chymostatin.Experimental
CilastatinThe serum concentration of Amineptine can be increased when it is combined with Cilastatin.Approved
CilazaprilThe serum concentration of Amineptine can be increased when it is combined with Cilazapril.Approved
CimetidineThe metabolism of Amineptine can be decreased when combined with Cimetidine.Approved
CinacalcetThe serum concentration of Amineptine can be increased when it is combined with Cinacalcet.Approved
CirazolineAmineptine may increase the vasopressor activities of Cirazoline.Experimental
CitalopramThe risk or severity of adverse effects can be increased when Amineptine is combined with Citalopram.Approved
ClenbuterolThe risk or severity of adverse effects can be increased when Amineptine is combined with Clenbuterol.Approved, Vet Approved
ClonidineAmineptine may decrease the antihypertensive activities of Clonidine.Approved
Dabigatran etexilateThe serum concentration of Amineptine can be increased when it is combined with Dabigatran etexilate.Approved
DarunavirThe serum concentration of Amineptine can be increased when it is combined with Darunavir.Approved
DesmopressinThe risk or severity of adverse effects can be increased when Amineptine is combined with Desmopressin.Approved
DexmedetomidineAmineptine may decrease the antihypertensive activities of Dexmedetomidine.Approved, Vet Approved
DexmethylphenidateThe risk or severity of adverse effects can be increased when Dexmethylphenidate is combined with Amineptine.Approved
DextroamphetamineAmineptine may increase the stimulatory activities of Dextroamphetamine.Approved, Illicit
DicoumarolAmineptine may increase the anticoagulant activities of Dicoumarol.Approved
DiethylpropionAmineptine may increase the stimulatory activities of Diethylpropion.Approved, Illicit
DihydroergotamineAmineptine may decrease the antihypertensive activities of Dihydroergotamine.Approved
DipivefrinAmineptine may decrease the antihypertensive activities of Dipivefrin.Approved
DobutamineThe risk or severity of adverse effects can be increased when Amineptine is combined with Dobutamine.Approved
DroxidopaAmineptine may decrease the antihypertensive activities of Droxidopa.Approved, Investigational
DuloxetineDuloxetine may increase the serotonergic activities of Amineptine.Approved
EcabetThe serum concentration of Amineptine can be increased when it is combined with Ecabet.Approved, Investigational
EdoxabanThe serum concentration of Amineptine can be increased when it is combined with Edoxaban.Approved
ElafinThe serum concentration of Amineptine can be increased when it is combined with Elafin.Investigational
EnalaprilThe serum concentration of Amineptine can be increased when it is combined with Enalapril.Approved, Vet Approved
EnalaprilatThe serum concentration of Amineptine can be increased when it is combined with Enalaprilat.Approved
EnalkirenThe serum concentration of Amineptine can be increased when it is combined with Enalkiren.Experimental
EphedraAmineptine may decrease the antihypertensive activities of Ephedra.Approved, Nutraceutical, Withdrawn
EpinephrineAmineptine may decrease the antihypertensive activities of Epinephrine.Approved, Vet Approved
ErgotamineAmineptine may decrease the antihypertensive activities of Ergotamine.Approved
EscitalopramThe risk or severity of adverse effects can be increased when Amineptine is combined with Escitalopram.Approved, Investigational
Ethyl biscoumacetateAmineptine may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
EtomidateAmineptine may decrease the antihypertensive activities of Etomidate.Approved
FenoterolThe risk or severity of adverse effects can be increased when Amineptine is combined with Fenoterol.Approved
FluindioneAmineptine may increase the anticoagulant activities of Fluindione.Investigational
FluoxetineThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Amineptine.Approved, Vet Approved
FluvoxamineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Amineptine.Approved, Investigational
FormoterolThe risk or severity of adverse effects can be increased when Amineptine is combined with Formoterol.Approved, Investigational
FosamprenavirThe serum concentration of Amineptine can be increased when it is combined with Fosamprenavir.Approved
FosinoprilThe serum concentration of Amineptine can be increased when it is combined with Fosinopril.Approved
FurazolidoneFurazolidone may increase the serotonergic activities of Amineptine.Approved, Vet Approved
GabexateThe serum concentration of Amineptine can be increased when it is combined with Gabexate.Investigational
GeldanamycinThe serum concentration of Amineptine can be increased when it is combined with Geldanamycin.Experimental
GM6001The serum concentration of Amineptine can be increased when it is combined with GM6001.Experimental
GuanabenzAmineptine may decrease the antihypertensive activities of Guanabenz.Approved
GuanfacineAmineptine may decrease the antihypertensive activities of Guanfacine.Approved, Investigational
HexobarbitalThe metabolism of Amineptine can be increased when combined with Hexobarbital.Approved
HirulogThe serum concentration of Amineptine can be increased when it is combined with Hirulog.Experimental
HydracarbazineHydracarbazine may increase the serotonergic activities of Amineptine.Approved
Hydroxyamphetamine hydrobromideAmineptine may increase the stimulatory activities of Hydroxyamphetamine hydrobromide.Approved
idraparinuxThe serum concentration of Amineptine can be increased when it is combined with idraparinux.Investigational
ImidaprilThe serum concentration of Amineptine can be increased when it is combined with Imidapril.Investigational
IndacaterolThe risk or severity of adverse effects can be increased when Amineptine is combined with Indacaterol.Approved
IndinavirThe serum concentration of Amineptine can be increased when it is combined with Indinavir.Approved
IobenguaneThe therapeutic efficacy of Iobenguane can be decreased when used in combination with Amineptine.Approved
IproclozideIproclozide may increase the serotonergic activities of Amineptine.Withdrawn
IproniazidIproniazid may increase the serotonergic activities of Amineptine.Withdrawn
IsocarboxazidIsocarboxazid may increase the serotonergic activities of Amineptine.Approved
IsoetarineThe risk or severity of adverse effects can be increased when Amineptine is combined with Isoetarine.Approved
IsoflurophateThe serum concentration of Amineptine can be increased when it is combined with Isoflurophate.Approved, Withdrawn
IsoprenalineThe risk or severity of adverse effects can be increased when Amineptine is combined with Isoprenaline.Approved
IxazomibThe serum concentration of Amineptine can be increased when it is combined with Ixazomib.Approved
LepirudinThe serum concentration of Amineptine can be increased when it is combined with Lepirudin.Approved
LevothyroxineLevothyroxine may increase the arrhythmogenic activities of Amineptine.Approved
LinagliptinThe serum concentration of Amineptine can be increased when it is combined with Linagliptin.Approved
LinezolidLinezolid may increase the serotonergic activities of Amineptine.Approved, Investigational
LiothyronineLiothyronine may increase the arrhythmogenic activities of Amineptine.Approved, Vet Approved
LiotrixLiotrix may increase the arrhythmogenic activities of Amineptine.Approved
LisdexamfetamineAmineptine may increase the stimulatory activities of Lisdexamfetamine.Approved, Investigational
LisinoprilThe serum concentration of Amineptine can be increased when it is combined with Lisinopril.Approved, Investigational
LithiumLithium may increase the neurotoxic activities of Amineptine.Approved
LofexidineAmineptine may decrease the antihypertensive activities of Lofexidine.Approved, Investigational
LopinavirThe serum concentration of Amineptine can be increased when it is combined with Lopinavir.Approved
MebanazineMebanazine may increase the serotonergic activities of Amineptine.Withdrawn
MephedroneAmineptine may increase the stimulatory activities of Mephedrone.Investigational
MephentermineAmineptine may increase the vasopressor activities of Mephentermine.Approved
MetaraminolAmineptine may increase the vasopressor activities of Metaraminol.Approved, Investigational
MethamphetamineAmineptine may decrease the antihypertensive activities of Methamphetamine.Approved, Illicit
MethohexitalThe metabolism of Amineptine can be increased when combined with Methohexital.Approved
MethoxamineAmineptine may increase the vasopressor activities of Methoxamine.Approved
Methylene blueAmineptine may increase the serotonergic activities of Methylene blue.Investigational
MethylphenidateThe risk or severity of adverse effects can be increased when Methylphenidate is combined with Amineptine.Approved, Investigational
MethylphenobarbitalThe metabolism of Amineptine can be increased when combined with Methylphenobarbital.Approved
MetoclopramideThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Amineptine.Approved, Investigational
MetyrosineThe risk or severity of adverse effects can be increased when Metyrosine is combined with Amineptine.Approved
MidodrineAmineptine may increase the vasopressor activities of Midodrine.Approved
MinaprineMinaprine may increase the serotonergic activities of Amineptine.Approved
MMDAAmineptine may increase the stimulatory activities of MMDA.Experimental, Illicit
MoclobemideMoclobemide may increase the serotonergic activities of Amineptine.Approved
MoexiprilThe serum concentration of Amineptine can be increased when it is combined with Moexipril.Approved
MoxonidineThe therapeutic efficacy of Moxonidine can be decreased when used in combination with Amineptine.Approved
N-(3-Propylcarbamoyloxirane-2-Carbonyl)-Isoleucyl-ProlineThe serum concentration of Amineptine can be increased when it is combined with N-(3-Propylcarbamoyloxirane-2-Carbonyl)-Isoleucyl-Proline.Experimental
NafamostatThe serum concentration of Amineptine can be increased when it is combined with Nafamostat.Investigational
NaphazolineAmineptine may decrease the antihypertensive activities of Naphazoline.Approved
NCX 4016The serum concentration of Amineptine can be increased when it is combined with NCX 4016.Investigational
NelfinavirThe serum concentration of Amineptine can be increased when it is combined with Nelfinavir.Approved
NialamideNialamide may increase the serotonergic activities of Amineptine.Withdrawn
NicorandilAmineptine may increase the hypotensive activities of Nicorandil.Approved
NitroaspirinThe serum concentration of Amineptine can be increased when it is combined with Nitroaspirin.Investigational
NorepinephrineAmineptine may decrease the antihypertensive activities of Norepinephrine.Approved
OctamoxinOctamoxin may increase the serotonergic activities of Amineptine.Withdrawn
OlodaterolThe risk or severity of adverse effects can be increased when Amineptine is combined with Olodaterol.Approved
OmapatrilatThe serum concentration of Amineptine can be increased when it is combined with Omapatrilat.Investigational
OrciprenalineThe risk or severity of adverse effects can be increased when Amineptine is combined with Orciprenaline.Approved
OtamixabanThe serum concentration of Amineptine can be increased when it is combined with Otamixaban.Investigational
OxymetazolineAmineptine may decrease the antihypertensive activities of Oxymetazoline.Approved
PaliperidoneAmineptine may decrease the antihypertensive activities of Paliperidone.Approved
PargylinePargyline may increase the serotonergic activities of Amineptine.Approved
ParoxetineThe risk or severity of adverse effects can be increased when Paroxetine is combined with Amineptine.Approved, Investigational
PentobarbitalThe metabolism of Amineptine can be increased when combined with Pentobarbital.Approved, Vet Approved
PergolideAmineptine may decrease the antihypertensive activities of Pergolide.Approved, Vet Approved, Withdrawn
PerindoprilThe serum concentration of Amineptine can be increased when it is combined with Perindopril.Approved
PhenelzinePhenelzine may increase the serotonergic activities of Amineptine.Approved
PhenindioneAmineptine may increase the anticoagulant activities of Phenindione.Approved
PheniprazinePheniprazine may increase the serotonergic activities of Amineptine.Withdrawn
PhenobarbitalThe metabolism of Amineptine can be increased when combined with Phenobarbital.Approved
PhenoxypropazinePhenoxypropazine may increase the serotonergic activities of Amineptine.Withdrawn
PhenprocoumonAmineptine may increase the anticoagulant activities of Phenprocoumon.Approved
PhentermineAmineptine may increase the stimulatory activities of Phentermine.Approved, Illicit
PhenylephrineAmineptine may increase the vasopressor activities of Phenylephrine.Approved
PhenylpropanolamineAmineptine may decrease the antihypertensive activities of Phenylpropanolamine.Approved, Vet Approved, Withdrawn
PhosphoramidonThe serum concentration of Amineptine can be increased when it is combined with Phosphoramidon.Experimental
PirbuterolThe risk or severity of adverse effects can be increased when Amineptine is combined with Pirbuterol.Approved
PirlindolePirlindole may increase the serotonergic activities of Amineptine.Approved
PivhydrazinePivhydrazine may increase the serotonergic activities of Amineptine.Withdrawn
PrimidoneThe metabolism of Amineptine can be increased when combined with Primidone.Approved, Vet Approved
PrinomastatThe serum concentration of Amineptine can be increased when it is combined with Prinomastat.Investigational
ProcaterolThe risk or severity of adverse effects can be increased when Amineptine is combined with Procaterol.Approved
PseudoephedrineAmineptine may decrease the antihypertensive activities of Pseudoephedrine.Approved
QuinaprilThe serum concentration of Amineptine can be increased when it is combined with Quinapril.Approved, Investigational
QuinidineAmineptine may increase the QTc-prolonging activities of Quinidine.Approved
RacecadotrilThe serum concentration of Amineptine can be increased when it is combined with Racecadotril.Investigational
RamiprilThe serum concentration of Amineptine can be increased when it is combined with Ramipril.Approved
RasagilineRasagiline may increase the serotonergic activities of Amineptine.Approved
RemikirenThe serum concentration of Amineptine can be increased when it is combined with Remikiren.Approved
RisperidoneAmineptine may decrease the antihypertensive activities of Risperidone.Approved, Investigational
RitobegronAmineptine may increase the stimulatory activities of Ritobegron.Investigational
RitodrineThe risk or severity of adverse effects can be increased when Amineptine is combined with Ritodrine.Approved
RitonavirThe serum concentration of Amineptine can be increased when it is combined with Ritonavir.Approved, Investigational
RivaroxabanThe serum concentration of Amineptine can be increased when it is combined with Rivaroxaban.Approved
RopiniroleAmineptine may decrease the antihypertensive activities of Ropinirole.Approved, Investigational
SafrazineSafrazine may increase the serotonergic activities of Amineptine.Withdrawn
SalbutamolThe risk or severity of adverse effects can be increased when Amineptine is combined with Salbutamol.Approved, Vet Approved
SalmeterolThe risk or severity of adverse effects can be increased when Amineptine is combined with Salmeterol.Approved
SaquinavirThe serum concentration of Amineptine can be increased when it is combined with Saquinavir.Approved, Investigational
SaxagliptinThe serum concentration of Amineptine can be increased when it is combined with Saxagliptin.Approved
SecobarbitalThe metabolism of Amineptine can be increased when combined with Secobarbital.Approved, Vet Approved
SelegilineSelegiline may increase the serotonergic activities of Amineptine.Approved, Investigational, Vet Approved
SertralineThe risk or severity of adverse effects can be increased when Sertraline is combined with Amineptine.Approved
SimeprevirThe serum concentration of Amineptine can be increased when it is combined with Simeprevir.Approved
SitagliptinThe serum concentration of Amineptine can be increased when it is combined with Sitagliptin.Approved, Investigational
SpiraprilThe serum concentration of Amineptine can be increased when it is combined with Spirapril.Approved
St. John's WortThe metabolism of Amineptine can be increased when combined with St. John's Wort.Nutraceutical
TelaprevirThe serum concentration of Amineptine can be increased when it is combined with Telaprevir.Approved
TemocaprilThe serum concentration of Amineptine can be increased when it is combined with Temocapril.Experimental, Investigational
TerbinafineThe metabolism of Amineptine can be decreased when combined with Terbinafine.Approved, Investigational, Vet Approved
TerbutalineThe risk or severity of adverse effects can be increased when Amineptine is combined with Terbutaline.Approved
ThiamylalThe metabolism of Amineptine can be increased when combined with Thiamylal.Approved, Vet Approved
ThiopentalThe metabolism of Amineptine can be increased when combined with Thiopental.Approved, Vet Approved
ThiorphanThe serum concentration of Amineptine can be increased when it is combined with Thiorphan.Experimental
Thyroid, porcineThyroid, porcine may increase the arrhythmogenic activities of Amineptine.Approved
TipranavirThe serum concentration of Amineptine can be increased when it is combined with Tipranavir.Approved, Investigational
TizanidineAmineptine may decrease the antihypertensive activities of Tizanidine.Approved
ToloxatoneToloxatone may increase the serotonergic activities of Amineptine.Approved
TramadolAmineptine may increase the neuroexcitatory activities of Tramadol.Approved, Investigational
TrandolaprilThe serum concentration of Amineptine can be increased when it is combined with Trandolapril.Approved
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the serotonergic activities of Amineptine.Experimental
TranylcypromineTranylcypromine may increase the serotonergic activities of Amineptine.Approved
UbenimexThe serum concentration of Amineptine can be increased when it is combined with Ubenimex.Experimental
UlinastatinThe serum concentration of Amineptine can be increased when it is combined with Ulinastatin.Investigational
Valproic AcidThe serum concentration of Amineptine can be increased when it is combined with Valproic Acid.Approved, Investigational
VilanterolThe risk or severity of adverse effects can be increased when Amineptine is combined with Vilanterol.Approved
VildagliptinThe serum concentration of Amineptine can be increased when it is combined with Vildagliptin.Approved, Investigational
WarfarinAmineptine may increase the anticoagulant activities of Warfarin.Approved
XimelagatranThe serum concentration of Amineptine can be increased when it is combined with Ximelagatran.Approved, Investigational, Withdrawn
XylometazolineAmineptine may decrease the antihypertensive activities of Xylometazoline.Approved
Ym150The serum concentration of Amineptine can be increased when it is combined with Ym150.Investigational
YohimbineThe serum concentration of Yohimbine can be increased when it is combined with Amineptine.Approved, Vet Approved
Food Interactions
  • Avoid alcohol.
  • Avoid excessive quantities of coffee or tea (Caffeine).
  • Avoid St.John's Wort.
  • Take with food to reduce irritation.
References
Synthesis Reference

Melen,C., Danree, B.and Poignant, J.C.; US.Patent 3,758,528; September 11,1973; assigned to Societe en nom Collectif Science Union et Cie; Societe Francaise de Recherche Medicale.
Melen, C., Danree, B. and Poignant, J.C.; U.S. Patent 3,821,249; June 28, 1974; assigned to Societe en nom Collectif Science Union et Cie; Societe Francaise de Recherche Medicale.

US3758528
General References
  1. Vaugeois JM, Corera AT, Deslandes A, Costentin J: Although chemically related to amineptine, the antidepressant tianeptine is not a dopamine uptake inhibitor. Pharmacol Biochem Behav. 1999 Jun;63(2):285-90. [PubMed:10371658 ]
  2. Grupper C: [New iatrogenic acne: acne caused by amineptin (Survector)]. Ann Dermatol Venereol. 1988;115(11):1174-6. [PubMed:2977079 ]
  3. Thioly-Bensoussan D, Charpentier A, Triller R, Thioly F, Blanchet P, Tricoire N, Noury JY, Grupper C: [Iatrogenic acne caused by amineptin (Survector). Apropos of 8 cases]. Ann Dermatol Venereol. 1988;115(11):1177-80. [PubMed:2977080 ]
  4. Vexiau P, Gourmel B, Husson C, Castot A, Rybojad M, Julien R, Fiet J, Puissant A, Cathelineau G: [Severe lesions of acne type induced by chronic amineptin poisoning: apropos of 6 cases]. Ann Dermatol Venereol. 1988;115(11):1180-2. [PubMed:2977081 ]
  5. Teillac D, Weber MJ, Lowenstein W, de Prost Y: [Acne caused by Survector]. Ann Dermatol Venereol. 1988;115(11):1183-4. [PubMed:2977082 ]
External Links
ATC CodesN06AA19
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.927
Blood Brain Barrier+0.9384
Caco-2 permeable-0.5548
P-glycoprotein substrateNon-substrate0.5457
P-glycoprotein inhibitor INon-inhibitor0.9324
P-glycoprotein inhibitor IINon-inhibitor0.8538
Renal organic cation transporterNon-inhibitor0.6998
CYP450 2C9 substrateNon-substrate0.7559
CYP450 2D6 substrateNon-substrate0.7653
CYP450 3A4 substrateNon-substrate0.5897
CYP450 1A2 substrateNon-inhibitor0.5434
CYP450 2C9 inhibitorNon-inhibitor0.8792
CYP450 2D6 inhibitorNon-inhibitor0.7593
CYP450 2C19 inhibitorNon-inhibitor0.8446
CYP450 3A4 inhibitorNon-inhibitor0.7073
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9165
Ames testAMES toxic0.6805
CarcinogenicityNon-carcinogens0.8651
BiodegradationNot ready biodegradable0.7096
Rat acute toxicity2.9526 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9341
hERG inhibition (predictor II)Inhibitor0.6018
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage formsNot Available
PricesNot Available
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point226-230Melen,C., Danree, B.and Poignant, J.C.; US.Patent 3,758,528; September 11,1973; assigned to Societe en nom Collectif Science Union et Cie; Societe Francaise de Recherche Medicale Melen, C., Danree, B. and Poignant, J.C.; U.S. Patent 3,821,249; June 28, 1974; assigned to Societe en nom Collectif Science Union et Cie; Societe Francaise de Recherche Medicale
Predicted Properties
PropertyValueSource
Water Solubility1.84e-05 mg/mLALOGPS
logP0.99ALOGPS
logP2.74ChemAxon
logS-7.3ALOGPS
pKa (Strongest Acidic)4.41ChemAxon
pKa (Strongest Basic)9.46ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area53.91 Å2ChemAxon
Rotatable Bond Count8ChemAxon
Refractivity112.63 m3·mol-1ChemAxon
Polarizability39.95 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
SpectraNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as dibenzocycloheptenes. These are compounds containing a dibenzocycloheptene moiety, which consists of two benzene connected by a cycloheptene ring.
KingdomOrganic compounds
Super ClassBenzenoids
ClassDibenzocycloheptenes
Sub ClassNot Available
Direct ParentDibenzocycloheptenes
Alternative Parents
Substituents
  • Dibenzocycloheptene
  • Carbocyclic fatty acid
  • Medium-chain fatty acid
  • Aralkylamine
  • Fatty acyl
  • Fatty acid
  • Quaternary ammonium salt
  • Monocarboxylic acid or derivatives
  • Carboxylic acid
  • Carboxylic acid derivative
  • Hydrocarbon derivative
  • Organic chloride salt
  • Organic salt
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Amine
  • Organic zwitterion
  • Aromatic homopolycyclic compound
Molecular FrameworkAromatic homopolycyclic compounds
External Descriptors

Targets

Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Norepinephrine:sodium symporter activity
Specific Function:
Amine transporter. Terminates the action of noradrenaline by its high affinity sodium-dependent reuptake into presynaptic terminals.
Gene Name:
SLC6A2
Uniprot ID:
P23975
Molecular Weight:
69331.42 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Serotonin:sodium symporter activity
Specific Function:
Serotonin transporter whose primary function in the central nervous system involves the regulation of serotonergic signaling via transport of serotonin molecules from the synaptic cleft back into the pre-synaptic terminal for re-utilization. Plays a key role in mediating regulation of the availability of serotonin to other receptors of serotonergic systems. Terminates the action of serotonin an...
Gene Name:
SLC6A4
Uniprot ID:
P31645
Molecular Weight:
70324.165 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
Comments
comments powered by Disqus
Drug created on September 12, 2007 03:05 / Updated on August 17, 2016 12:24